**Cystic Fibrosis Trust response to today’s statement from NHS England on life-saving cystic fibrosis drugs**

NHS England have today set out a new proposal to the manufacturer of Kalydeco, Orkambi and Symkevi, Vertex Pharmaceuticals. Their letter suggests they have made a “significant increase” to their financial proposal per patient for Orkambi and Symkevi, and have made a new offer to extend availability of Kalydeco on the NHS. Full NHS statement [here](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.parliament.uk%2Fdocuments%2Fcommons-committees%2FHealth%2FCorrespondence%2F2017-19%2F19-05-23-NHS-England-update-availability-of-Orkambi-on-the-NHS.pdf&data=02%7C01%7Cadam.harley%40cysticfibrosis.org.uk%7C4ac471ec258446c883a408d6df8b3e3b%7C6c5164ba244b424b8334339091110751%7C0%7C0%7C636942186471675636&sdata=AbFHz0TDflzMBw1jgVX8%2BLS4nwrJWPjkKVKre0PY9H4%3D&reserved=0)

**David Ramsden, chief executive of the Cystic Fibrosis Trust, said: “After weeks of painful silence, we now know that NHS England have offered the pharma company Vertex a new price for the life-saving cystic fibrosis drugs Orkambi and Symkevi. They’ve also proposed a two-year access system which could  give the drugs to people immediately. But this means nothing without agreement from all sides. We ask Vertex for an immediate response.”**

The Cystic Fibrosis Trust described the principles of managed access to support reimbursement decision-making in a [proposal presented to all parties](https://www.cysticfibrosis.org.uk/~/media/documents/news/orkambi--cystic-fibrosis-trust-access-solution-%283%29.ashx) in 2015. We are pleased to see important elements of this proposal reflected in NHS England’s letter today.